Global Cognitive Decline Treatment Supply, Demand and Key Producers, 2026-2032
The global Cognitive Decline Treatment market size is expected to reach $ 248320 million by 2032, rising at a market growth of 7.0% CAGR during the forecast period (2026-2032).
Cognitive decline treatment refers to a comprehensive medical intervention system that addresses the decline in memory, attention, executive function, and language abilities caused by aging, neurodegenerative diseases, brain injury, or metabolic diseases. It utilizes a combination of methods, including drug therapy, non-drug interventions, neuromodulation techniques, and digital therapies, to slow or improve the progression of cognitive decline. Its core objectives are to slow disease progression, improve patients' daily living abilities, and enhance their quality of life.
With the accelerating aging of the global population and the rapid increase in the number of people aged 65 and above, the incidence of cognitive decline-related diseases continues to rise, significantly expanding the demand for treatment and intervention. Simultaneously, in drug development, the entry of A? monoclonal antibodies into clinical application marks a breakthrough in disease-modifying therapy (DMT). Coupled with the development of digital therapies, AI-based early screening tools, brain-computer interfaces, and neuromodulation technologies, cognitive decline treatment is evolving from single-drug therapy to a comprehensive solution encompassing 'drugs + devices + digital therapies + rehabilitation management.' The market is expected to continue its rapid growth in the future, extending towards early screening, delaying onset, and long-term management.
This report studies the global Cognitive Decline Treatment demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Cognitive Decline Treatment, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Cognitive Decline Treatment that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Cognitive Decline Treatment total market, 2021-2032, (USD Million)
Global Cognitive Decline Treatment total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Cognitive Decline Treatment total market, key domestic companies, and share, (USD Million)
Global Cognitive Decline Treatment revenue by player, revenue and market share 2021-2026, (USD Million)
Global Cognitive Decline Treatment total market by Type, CAGR, 2021-2032, (USD Million)
Global Cognitive Decline Treatment total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Cognitive Decline Treatment market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Eli Lilly and Company, Eisai Co., Ltd, Biogen Inc., Novartis AG, AbbVie Inc., Lundbeck, Takeda Pharmaceutical, Alzheon, TauRx Therapeutics, Medtronic, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Cognitive Decline Treatment market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Cognitive Decline Treatment Market, By Region:
1. How big is the global Cognitive Decline Treatment market?
2. What is the demand of the global Cognitive Decline Treatment market?
3. What is the year over year growth of the global Cognitive Decline Treatment market?
4. What is the total value of the global Cognitive Decline Treatment market?
5. Who are the Major Players in the global Cognitive Decline Treatment market?
6. What are the growth factors driving the market demand?
Cognitive decline treatment refers to a comprehensive medical intervention system that addresses the decline in memory, attention, executive function, and language abilities caused by aging, neurodegenerative diseases, brain injury, or metabolic diseases. It utilizes a combination of methods, including drug therapy, non-drug interventions, neuromodulation techniques, and digital therapies, to slow or improve the progression of cognitive decline. Its core objectives are to slow disease progression, improve patients' daily living abilities, and enhance their quality of life.
With the accelerating aging of the global population and the rapid increase in the number of people aged 65 and above, the incidence of cognitive decline-related diseases continues to rise, significantly expanding the demand for treatment and intervention. Simultaneously, in drug development, the entry of A? monoclonal antibodies into clinical application marks a breakthrough in disease-modifying therapy (DMT). Coupled with the development of digital therapies, AI-based early screening tools, brain-computer interfaces, and neuromodulation technologies, cognitive decline treatment is evolving from single-drug therapy to a comprehensive solution encompassing 'drugs + devices + digital therapies + rehabilitation management.' The market is expected to continue its rapid growth in the future, extending towards early screening, delaying onset, and long-term management.
This report studies the global Cognitive Decline Treatment demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Cognitive Decline Treatment, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Cognitive Decline Treatment that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Cognitive Decline Treatment total market, 2021-2032, (USD Million)
Global Cognitive Decline Treatment total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Cognitive Decline Treatment total market, key domestic companies, and share, (USD Million)
Global Cognitive Decline Treatment revenue by player, revenue and market share 2021-2026, (USD Million)
Global Cognitive Decline Treatment total market by Type, CAGR, 2021-2032, (USD Million)
Global Cognitive Decline Treatment total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Cognitive Decline Treatment market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Eli Lilly and Company, Eisai Co., Ltd, Biogen Inc., Novartis AG, AbbVie Inc., Lundbeck, Takeda Pharmaceutical, Alzheon, TauRx Therapeutics, Medtronic, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Cognitive Decline Treatment market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Cognitive Decline Treatment Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Prescription Drugs
- Medical Devices
- Digital Therapy Software
- Rehabilitation Training Services
- Others
- Prevention Stage
- Early Intervention
- Intermediate Treatment
- Late-Stage Supportive Treatment
- Neurotransmitter Regulation Pathway
- Amyloid (A?) Clearance Pathway
- Tau Protein Targeting Pathway
- Neuroinflammatory Regulation Pathway
- Neuroplasticity Enhancement Pathway
- Alzheimer's Disease (AD)
- Vascular Cognitive Impairment (VCI)
- Parkinson's-Related Cognitive Decline
- Post-Traumatic Brain Injury Cognitive Impairment
- Mild Cognitive Impairment (MCI)
- Eli Lilly and Company
- Eisai Co., Ltd
- Biogen Inc.
- Novartis AG
- AbbVie Inc.
- Lundbeck
- Takeda Pharmaceutical
- Alzheon
- TauRx Therapeutics
- Medtronic
- Abbott Laboratories
- Boston Scientific
- NeuroPace
- Posit Science
- CogniFit
- Linus Health
- BrainCheck
- Eisai
- Ono Pharmaceutical
- Takeda Pharmaceutical
- SK Biopharmaceuticals
- VUNO
- Ybrain
- Green Valley Pharma
- Neusoft Medical
1. How big is the global Cognitive Decline Treatment market?
2. What is the demand of the global Cognitive Decline Treatment market?
3. What is the year over year growth of the global Cognitive Decline Treatment market?
4. What is the total value of the global Cognitive Decline Treatment market?
5. Who are the Major Players in the global Cognitive Decline Treatment market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Cognitive Decline Treatment Introduction
1.2 World Cognitive Decline Treatment Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Cognitive Decline Treatment Total Market by Region (by Headquarter Location)
1.3.1 World Cognitive Decline Treatment Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Cognitive Decline Treatment Revenue (2021-2032)
1.3.3 China Based Company Cognitive Decline Treatment Revenue (2021-2032)
1.3.4 Europe Based Company Cognitive Decline Treatment Revenue (2021-2032)
1.3.5 Japan Based Company Cognitive Decline Treatment Revenue (2021-2032)
1.3.6 South Korea Based Company Cognitive Decline Treatment Revenue (2021-2032)
1.3.7 ASEAN Based Company Cognitive Decline Treatment Revenue (2021-2032)
1.3.8 India Based Company Cognitive Decline Treatment Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Cognitive Decline Treatment Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Cognitive Decline Treatment Consumption Value (2021-2032)
2.2 World Cognitive Decline Treatment Consumption Value by Region
2.2.1 World Cognitive Decline Treatment Consumption Value by Region (2021-2026)
2.2.2 World Cognitive Decline Treatment Consumption Value Forecast by Region (2027-2032)
2.3 United States Cognitive Decline Treatment Consumption Value (2021-2032)
2.4 China Cognitive Decline Treatment Consumption Value (2021-2032)
2.5 Europe Cognitive Decline Treatment Consumption Value (2021-2032)
2.6 Japan Cognitive Decline Treatment Consumption Value (2021-2032)
2.7 South Korea Cognitive Decline Treatment Consumption Value (2021-2032)
2.8 ASEAN Cognitive Decline Treatment Consumption Value (2021-2032)
2.9 India Cognitive Decline Treatment Consumption Value (2021-2032)
3 WORLD COGNITIVE DECLINE TREATMENT COMPANIES COMPETITIVE ANALYSIS
3.1 World Cognitive Decline Treatment Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Cognitive Decline Treatment Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Cognitive Decline Treatment in 2025
3.2.3 Global Concentration Ratios (CR8) for Cognitive Decline Treatment in 2025
3.3 Cognitive Decline Treatment Company Evaluation Quadrant
3.4 Cognitive Decline Treatment Market: Overall Company Footprint Analysis
3.4.1 Cognitive Decline Treatment Market: Region Footprint
3.4.2 Cognitive Decline Treatment Market: Company Product Type Footprint
3.4.3 Cognitive Decline Treatment Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Cognitive Decline Treatment Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Cognitive Decline Treatment Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Cognitive Decline Treatment Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Cognitive Decline Treatment Consumption Value Comparison
4.2.1 United States VS China: Cognitive Decline Treatment Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Cognitive Decline Treatment Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Cognitive Decline Treatment Companies and Market Share, 2021-2026
4.3.1 United States Based Cognitive Decline Treatment Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Cognitive Decline Treatment Revenue, (2021-2026)
4.4 China Based Companies Cognitive Decline Treatment Revenue and Market Share, 2021-2026
4.4.1 China Based Cognitive Decline Treatment Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Cognitive Decline Treatment Revenue, (2021-2026)
4.5 Rest of World Based Cognitive Decline Treatment Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Cognitive Decline Treatment Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Cognitive Decline Treatment Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Cognitive Decline Treatment Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Prescription Drugs
5.2.2 Medical Devices
5.2.3 Digital Therapy Software
5.2.4 Rehabilitation Training Services
5.2.5 Others
5.3 Market Segment by Type
5.3.1 World Cognitive Decline Treatment Market Size by Type (2021-2026)
5.3.2 World Cognitive Decline Treatment Market Size by Type (2027-2032)
5.3.3 World Cognitive Decline Treatment Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY INTERVENTION STAGES
6.1 World Cognitive Decline Treatment Market Size Overview by Intervention Stages: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Intervention Stages
6.2.1 Prevention Stage
6.2.2 Early Intervention
6.2.3 Intermediate Treatment
6.2.4 Late-Stage Supportive Treatment
6.3 Market Segment by Intervention Stages
6.3.1 World Cognitive Decline Treatment Market Size by Intervention Stages (2021-2026)
6.3.2 World Cognitive Decline Treatment Market Size by Intervention Stages (2027-2032)
6.3.3 World Cognitive Decline Treatment Market Size Market Share by Intervention Stages (2027-2032)
7 MARKET ANALYSIS BY TECHNOLOGICAL PATHWAYS
7.1 World Cognitive Decline Treatment Market Size Overview by Technological Pathways: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Technological Pathways
7.2.1 Neurotransmitter Regulation Pathway
7.2.2 Amyloid (A?) Clearance Pathway
7.2.3 Tau Protein Targeting Pathway
7.2.4 Neuroinflammatory Regulation Pathway
7.2.5 Neuroplasticity Enhancement Pathway
7.3 Market Segment by Technological Pathways
7.3.1 World Cognitive Decline Treatment Market Size by Technological Pathways (2021-2026)
7.3.2 World Cognitive Decline Treatment Market Size by Technological Pathways (2027-2032)
7.3.3 World Cognitive Decline Treatment Market Size Market Share by Technological Pathways (2027-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Cognitive Decline Treatment Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Alzheimer's Disease (AD)
8.2.2 Vascular Cognitive Impairment (VCI)
8.2.3 Parkinson's-Related Cognitive Decline
8.2.4 Post-Traumatic Brain Injury Cognitive Impairment
8.2.5 Mild Cognitive Impairment (MCI)
8.3 Market Segment by Application
8.3.1 World Cognitive Decline Treatment Market Size by Application (2021-2026)
8.3.2 World Cognitive Decline Treatment Market Size by Application (2027-2032)
8.3.3 World Cognitive Decline Treatment Market Size Market Share by Application (2021-2032)
9 COMPANY PROFILES
9.1 Eli Lilly and Company
9.1.1 Eli Lilly and Company Details
9.1.2 Eli Lilly and Company Major Business
9.1.3 Eli Lilly and Company Cognitive Decline Treatment Product and Services
9.1.4 Eli Lilly and Company Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.1.5 Eli Lilly and Company Recent Developments/Updates
9.1.6 Eli Lilly and Company Competitive Strengths & Weaknesses
9.2 Eisai Co., Ltd
9.2.1 Eisai Co., Ltd Details
9.2.2 Eisai Co., Ltd Major Business
9.2.3 Eisai Co., Ltd Cognitive Decline Treatment Product and Services
9.2.4 Eisai Co., Ltd Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.2.5 Eisai Co., Ltd Recent Developments/Updates
9.2.6 Eisai Co., Ltd Competitive Strengths & Weaknesses
9.3 Biogen Inc.
9.3.1 Biogen Inc. Details
9.3.2 Biogen Inc. Major Business
9.3.3 Biogen Inc. Cognitive Decline Treatment Product and Services
9.3.4 Biogen Inc. Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.3.5 Biogen Inc. Recent Developments/Updates
9.3.6 Biogen Inc. Competitive Strengths & Weaknesses
9.4 Novartis AG
9.4.1 Novartis AG Details
9.4.2 Novartis AG Major Business
9.4.3 Novartis AG Cognitive Decline Treatment Product and Services
9.4.4 Novartis AG Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.4.5 Novartis AG Recent Developments/Updates
9.4.6 Novartis AG Competitive Strengths & Weaknesses
9.5 AbbVie Inc.
9.5.1 AbbVie Inc. Details
9.5.2 AbbVie Inc. Major Business
9.5.3 AbbVie Inc. Cognitive Decline Treatment Product and Services
9.5.4 AbbVie Inc. Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.5.5 AbbVie Inc. Recent Developments/Updates
9.5.6 AbbVie Inc. Competitive Strengths & Weaknesses
9.6 Lundbeck
9.6.1 Lundbeck Details
9.6.2 Lundbeck Major Business
9.6.3 Lundbeck Cognitive Decline Treatment Product and Services
9.6.4 Lundbeck Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.6.5 Lundbeck Recent Developments/Updates
9.6.6 Lundbeck Competitive Strengths & Weaknesses
9.7 Takeda Pharmaceutical
9.7.1 Takeda Pharmaceutical Details
9.7.2 Takeda Pharmaceutical Major Business
9.7.3 Takeda Pharmaceutical Cognitive Decline Treatment Product and Services
9.7.4 Takeda Pharmaceutical Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.7.5 Takeda Pharmaceutical Recent Developments/Updates
9.7.6 Takeda Pharmaceutical Competitive Strengths & Weaknesses
9.8 Alzheon
9.8.1 Alzheon Details
9.8.2 Alzheon Major Business
9.8.3 Alzheon Cognitive Decline Treatment Product and Services
9.8.4 Alzheon Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.8.5 Alzheon Recent Developments/Updates
9.8.6 Alzheon Competitive Strengths & Weaknesses
9.9 TauRx Therapeutics
9.9.1 TauRx Therapeutics Details
9.9.2 TauRx Therapeutics Major Business
9.9.3 TauRx Therapeutics Cognitive Decline Treatment Product and Services
9.9.4 TauRx Therapeutics Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.9.5 TauRx Therapeutics Recent Developments/Updates
9.9.6 TauRx Therapeutics Competitive Strengths & Weaknesses
9.10 Medtronic
9.10.1 Medtronic Details
9.10.2 Medtronic Major Business
9.10.3 Medtronic Cognitive Decline Treatment Product and Services
9.10.4 Medtronic Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.10.5 Medtronic Recent Developments/Updates
9.10.6 Medtronic Competitive Strengths & Weaknesses
9.11 Abbott Laboratories
9.11.1 Abbott Laboratories Details
9.11.2 Abbott Laboratories Major Business
9.11.3 Abbott Laboratories Cognitive Decline Treatment Product and Services
9.11.4 Abbott Laboratories Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.11.5 Abbott Laboratories Recent Developments/Updates
9.11.6 Abbott Laboratories Competitive Strengths & Weaknesses
9.12 Boston Scientific
9.12.1 Boston Scientific Details
9.12.2 Boston Scientific Major Business
9.12.3 Boston Scientific Cognitive Decline Treatment Product and Services
9.12.4 Boston Scientific Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.12.5 Boston Scientific Recent Developments/Updates
9.12.6 Boston Scientific Competitive Strengths & Weaknesses
9.13 NeuroPace
9.13.1 NeuroPace Details
9.13.2 NeuroPace Major Business
9.13.3 NeuroPace Cognitive Decline Treatment Product and Services
9.13.4 NeuroPace Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.13.5 NeuroPace Recent Developments/Updates
9.13.6 NeuroPace Competitive Strengths & Weaknesses
9.14 Posit Science
9.14.1 Posit Science Details
9.14.2 Posit Science Major Business
9.14.3 Posit Science Cognitive Decline Treatment Product and Services
9.14.4 Posit Science Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.14.5 Posit Science Recent Developments/Updates
9.14.6 Posit Science Competitive Strengths & Weaknesses
9.15 CogniFit
9.15.1 CogniFit Details
9.15.2 CogniFit Major Business
9.15.3 CogniFit Cognitive Decline Treatment Product and Services
9.15.4 CogniFit Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.15.5 CogniFit Recent Developments/Updates
9.15.6 CogniFit Competitive Strengths & Weaknesses
9.16 Linus Health
9.16.1 Linus Health Details
9.16.2 Linus Health Major Business
9.16.3 Linus Health Cognitive Decline Treatment Product and Services
9.16.4 Linus Health Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.16.5 Linus Health Recent Developments/Updates
9.16.6 Linus Health Competitive Strengths & Weaknesses
9.17 BrainCheck
9.17.1 BrainCheck Details
9.17.2 BrainCheck Major Business
9.17.3 BrainCheck Cognitive Decline Treatment Product and Services
9.17.4 BrainCheck Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.17.5 BrainCheck Recent Developments/Updates
9.17.6 BrainCheck Competitive Strengths & Weaknesses
9.18 Eisai
9.18.1 Eisai Details
9.18.2 Eisai Major Business
9.18.3 Eisai Cognitive Decline Treatment Product and Services
9.18.4 Eisai Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.18.5 Eisai Recent Developments/Updates
9.18.6 Eisai Competitive Strengths & Weaknesses
9.19 Ono Pharmaceutical
9.19.1 Ono Pharmaceutical Details
9.19.2 Ono Pharmaceutical Major Business
9.19.3 Ono Pharmaceutical Cognitive Decline Treatment Product and Services
9.19.4 Ono Pharmaceutical Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.19.5 Ono Pharmaceutical Recent Developments/Updates
9.19.6 Ono Pharmaceutical Competitive Strengths & Weaknesses
9.20 Takeda Pharmaceutical
9.20.1 Takeda Pharmaceutical Details
9.20.2 Takeda Pharmaceutical Major Business
9.20.3 Takeda Pharmaceutical Cognitive Decline Treatment Product and Services
9.20.4 Takeda Pharmaceutical Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.20.5 Takeda Pharmaceutical Recent Developments/Updates
9.20.6 Takeda Pharmaceutical Competitive Strengths & Weaknesses
9.21 SK Biopharmaceuticals
9.21.1 SK Biopharmaceuticals Details
9.21.2 SK Biopharmaceuticals Major Business
9.21.3 SK Biopharmaceuticals Cognitive Decline Treatment Product and Services
9.21.4 SK Biopharmaceuticals Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.21.5 SK Biopharmaceuticals Recent Developments/Updates
9.21.6 SK Biopharmaceuticals Competitive Strengths & Weaknesses
9.22 VUNO
9.22.1 VUNO Details
9.22.2 VUNO Major Business
9.22.3 VUNO Cognitive Decline Treatment Product and Services
9.22.4 VUNO Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.22.5 VUNO Recent Developments/Updates
9.22.6 VUNO Competitive Strengths & Weaknesses
9.23 Ybrain
9.23.1 Ybrain Details
9.23.2 Ybrain Major Business
9.23.3 Ybrain Cognitive Decline Treatment Product and Services
9.23.4 Ybrain Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.23.5 Ybrain Recent Developments/Updates
9.23.6 Ybrain Competitive Strengths & Weaknesses
9.24 Green Valley Pharma
9.24.1 Green Valley Pharma Details
9.24.2 Green Valley Pharma Major Business
9.24.3 Green Valley Pharma Cognitive Decline Treatment Product and Services
9.24.4 Green Valley Pharma Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.24.5 Green Valley Pharma Recent Developments/Updates
9.24.6 Green Valley Pharma Competitive Strengths & Weaknesses
9.25 Neusoft Medical
9.25.1 Neusoft Medical Details
9.25.2 Neusoft Medical Major Business
9.25.3 Neusoft Medical Cognitive Decline Treatment Product and Services
9.25.4 Neusoft Medical Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.25.5 Neusoft Medical Recent Developments/Updates
9.25.6 Neusoft Medical Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Cognitive Decline Treatment Industry Chain
10.2 Cognitive Decline Treatment Upstream Analysis
10.3 Cognitive Decline Treatment Midstream Analysis
10.4 Cognitive Decline Treatment Downstream Analysis
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
1.1 Cognitive Decline Treatment Introduction
1.2 World Cognitive Decline Treatment Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Cognitive Decline Treatment Total Market by Region (by Headquarter Location)
1.3.1 World Cognitive Decline Treatment Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Cognitive Decline Treatment Revenue (2021-2032)
1.3.3 China Based Company Cognitive Decline Treatment Revenue (2021-2032)
1.3.4 Europe Based Company Cognitive Decline Treatment Revenue (2021-2032)
1.3.5 Japan Based Company Cognitive Decline Treatment Revenue (2021-2032)
1.3.6 South Korea Based Company Cognitive Decline Treatment Revenue (2021-2032)
1.3.7 ASEAN Based Company Cognitive Decline Treatment Revenue (2021-2032)
1.3.8 India Based Company Cognitive Decline Treatment Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Cognitive Decline Treatment Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Cognitive Decline Treatment Consumption Value (2021-2032)
2.2 World Cognitive Decline Treatment Consumption Value by Region
2.2.1 World Cognitive Decline Treatment Consumption Value by Region (2021-2026)
2.2.2 World Cognitive Decline Treatment Consumption Value Forecast by Region (2027-2032)
2.3 United States Cognitive Decline Treatment Consumption Value (2021-2032)
2.4 China Cognitive Decline Treatment Consumption Value (2021-2032)
2.5 Europe Cognitive Decline Treatment Consumption Value (2021-2032)
2.6 Japan Cognitive Decline Treatment Consumption Value (2021-2032)
2.7 South Korea Cognitive Decline Treatment Consumption Value (2021-2032)
2.8 ASEAN Cognitive Decline Treatment Consumption Value (2021-2032)
2.9 India Cognitive Decline Treatment Consumption Value (2021-2032)
3 WORLD COGNITIVE DECLINE TREATMENT COMPANIES COMPETITIVE ANALYSIS
3.1 World Cognitive Decline Treatment Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Cognitive Decline Treatment Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Cognitive Decline Treatment in 2025
3.2.3 Global Concentration Ratios (CR8) for Cognitive Decline Treatment in 2025
3.3 Cognitive Decline Treatment Company Evaluation Quadrant
3.4 Cognitive Decline Treatment Market: Overall Company Footprint Analysis
3.4.1 Cognitive Decline Treatment Market: Region Footprint
3.4.2 Cognitive Decline Treatment Market: Company Product Type Footprint
3.4.3 Cognitive Decline Treatment Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Cognitive Decline Treatment Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Cognitive Decline Treatment Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Cognitive Decline Treatment Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Cognitive Decline Treatment Consumption Value Comparison
4.2.1 United States VS China: Cognitive Decline Treatment Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Cognitive Decline Treatment Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Cognitive Decline Treatment Companies and Market Share, 2021-2026
4.3.1 United States Based Cognitive Decline Treatment Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Cognitive Decline Treatment Revenue, (2021-2026)
4.4 China Based Companies Cognitive Decline Treatment Revenue and Market Share, 2021-2026
4.4.1 China Based Cognitive Decline Treatment Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Cognitive Decline Treatment Revenue, (2021-2026)
4.5 Rest of World Based Cognitive Decline Treatment Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Cognitive Decline Treatment Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Cognitive Decline Treatment Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Cognitive Decline Treatment Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Prescription Drugs
5.2.2 Medical Devices
5.2.3 Digital Therapy Software
5.2.4 Rehabilitation Training Services
5.2.5 Others
5.3 Market Segment by Type
5.3.1 World Cognitive Decline Treatment Market Size by Type (2021-2026)
5.3.2 World Cognitive Decline Treatment Market Size by Type (2027-2032)
5.3.3 World Cognitive Decline Treatment Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY INTERVENTION STAGES
6.1 World Cognitive Decline Treatment Market Size Overview by Intervention Stages: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Intervention Stages
6.2.1 Prevention Stage
6.2.2 Early Intervention
6.2.3 Intermediate Treatment
6.2.4 Late-Stage Supportive Treatment
6.3 Market Segment by Intervention Stages
6.3.1 World Cognitive Decline Treatment Market Size by Intervention Stages (2021-2026)
6.3.2 World Cognitive Decline Treatment Market Size by Intervention Stages (2027-2032)
6.3.3 World Cognitive Decline Treatment Market Size Market Share by Intervention Stages (2027-2032)
7 MARKET ANALYSIS BY TECHNOLOGICAL PATHWAYS
7.1 World Cognitive Decline Treatment Market Size Overview by Technological Pathways: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Technological Pathways
7.2.1 Neurotransmitter Regulation Pathway
7.2.2 Amyloid (A?) Clearance Pathway
7.2.3 Tau Protein Targeting Pathway
7.2.4 Neuroinflammatory Regulation Pathway
7.2.5 Neuroplasticity Enhancement Pathway
7.3 Market Segment by Technological Pathways
7.3.1 World Cognitive Decline Treatment Market Size by Technological Pathways (2021-2026)
7.3.2 World Cognitive Decline Treatment Market Size by Technological Pathways (2027-2032)
7.3.3 World Cognitive Decline Treatment Market Size Market Share by Technological Pathways (2027-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Cognitive Decline Treatment Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Alzheimer's Disease (AD)
8.2.2 Vascular Cognitive Impairment (VCI)
8.2.3 Parkinson's-Related Cognitive Decline
8.2.4 Post-Traumatic Brain Injury Cognitive Impairment
8.2.5 Mild Cognitive Impairment (MCI)
8.3 Market Segment by Application
8.3.1 World Cognitive Decline Treatment Market Size by Application (2021-2026)
8.3.2 World Cognitive Decline Treatment Market Size by Application (2027-2032)
8.3.3 World Cognitive Decline Treatment Market Size Market Share by Application (2021-2032)
9 COMPANY PROFILES
9.1 Eli Lilly and Company
9.1.1 Eli Lilly and Company Details
9.1.2 Eli Lilly and Company Major Business
9.1.3 Eli Lilly and Company Cognitive Decline Treatment Product and Services
9.1.4 Eli Lilly and Company Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.1.5 Eli Lilly and Company Recent Developments/Updates
9.1.6 Eli Lilly and Company Competitive Strengths & Weaknesses
9.2 Eisai Co., Ltd
9.2.1 Eisai Co., Ltd Details
9.2.2 Eisai Co., Ltd Major Business
9.2.3 Eisai Co., Ltd Cognitive Decline Treatment Product and Services
9.2.4 Eisai Co., Ltd Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.2.5 Eisai Co., Ltd Recent Developments/Updates
9.2.6 Eisai Co., Ltd Competitive Strengths & Weaknesses
9.3 Biogen Inc.
9.3.1 Biogen Inc. Details
9.3.2 Biogen Inc. Major Business
9.3.3 Biogen Inc. Cognitive Decline Treatment Product and Services
9.3.4 Biogen Inc. Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.3.5 Biogen Inc. Recent Developments/Updates
9.3.6 Biogen Inc. Competitive Strengths & Weaknesses
9.4 Novartis AG
9.4.1 Novartis AG Details
9.4.2 Novartis AG Major Business
9.4.3 Novartis AG Cognitive Decline Treatment Product and Services
9.4.4 Novartis AG Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.4.5 Novartis AG Recent Developments/Updates
9.4.6 Novartis AG Competitive Strengths & Weaknesses
9.5 AbbVie Inc.
9.5.1 AbbVie Inc. Details
9.5.2 AbbVie Inc. Major Business
9.5.3 AbbVie Inc. Cognitive Decline Treatment Product and Services
9.5.4 AbbVie Inc. Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.5.5 AbbVie Inc. Recent Developments/Updates
9.5.6 AbbVie Inc. Competitive Strengths & Weaknesses
9.6 Lundbeck
9.6.1 Lundbeck Details
9.6.2 Lundbeck Major Business
9.6.3 Lundbeck Cognitive Decline Treatment Product and Services
9.6.4 Lundbeck Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.6.5 Lundbeck Recent Developments/Updates
9.6.6 Lundbeck Competitive Strengths & Weaknesses
9.7 Takeda Pharmaceutical
9.7.1 Takeda Pharmaceutical Details
9.7.2 Takeda Pharmaceutical Major Business
9.7.3 Takeda Pharmaceutical Cognitive Decline Treatment Product and Services
9.7.4 Takeda Pharmaceutical Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.7.5 Takeda Pharmaceutical Recent Developments/Updates
9.7.6 Takeda Pharmaceutical Competitive Strengths & Weaknesses
9.8 Alzheon
9.8.1 Alzheon Details
9.8.2 Alzheon Major Business
9.8.3 Alzheon Cognitive Decline Treatment Product and Services
9.8.4 Alzheon Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.8.5 Alzheon Recent Developments/Updates
9.8.6 Alzheon Competitive Strengths & Weaknesses
9.9 TauRx Therapeutics
9.9.1 TauRx Therapeutics Details
9.9.2 TauRx Therapeutics Major Business
9.9.3 TauRx Therapeutics Cognitive Decline Treatment Product and Services
9.9.4 TauRx Therapeutics Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.9.5 TauRx Therapeutics Recent Developments/Updates
9.9.6 TauRx Therapeutics Competitive Strengths & Weaknesses
9.10 Medtronic
9.10.1 Medtronic Details
9.10.2 Medtronic Major Business
9.10.3 Medtronic Cognitive Decline Treatment Product and Services
9.10.4 Medtronic Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.10.5 Medtronic Recent Developments/Updates
9.10.6 Medtronic Competitive Strengths & Weaknesses
9.11 Abbott Laboratories
9.11.1 Abbott Laboratories Details
9.11.2 Abbott Laboratories Major Business
9.11.3 Abbott Laboratories Cognitive Decline Treatment Product and Services
9.11.4 Abbott Laboratories Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.11.5 Abbott Laboratories Recent Developments/Updates
9.11.6 Abbott Laboratories Competitive Strengths & Weaknesses
9.12 Boston Scientific
9.12.1 Boston Scientific Details
9.12.2 Boston Scientific Major Business
9.12.3 Boston Scientific Cognitive Decline Treatment Product and Services
9.12.4 Boston Scientific Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.12.5 Boston Scientific Recent Developments/Updates
9.12.6 Boston Scientific Competitive Strengths & Weaknesses
9.13 NeuroPace
9.13.1 NeuroPace Details
9.13.2 NeuroPace Major Business
9.13.3 NeuroPace Cognitive Decline Treatment Product and Services
9.13.4 NeuroPace Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.13.5 NeuroPace Recent Developments/Updates
9.13.6 NeuroPace Competitive Strengths & Weaknesses
9.14 Posit Science
9.14.1 Posit Science Details
9.14.2 Posit Science Major Business
9.14.3 Posit Science Cognitive Decline Treatment Product and Services
9.14.4 Posit Science Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.14.5 Posit Science Recent Developments/Updates
9.14.6 Posit Science Competitive Strengths & Weaknesses
9.15 CogniFit
9.15.1 CogniFit Details
9.15.2 CogniFit Major Business
9.15.3 CogniFit Cognitive Decline Treatment Product and Services
9.15.4 CogniFit Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.15.5 CogniFit Recent Developments/Updates
9.15.6 CogniFit Competitive Strengths & Weaknesses
9.16 Linus Health
9.16.1 Linus Health Details
9.16.2 Linus Health Major Business
9.16.3 Linus Health Cognitive Decline Treatment Product and Services
9.16.4 Linus Health Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.16.5 Linus Health Recent Developments/Updates
9.16.6 Linus Health Competitive Strengths & Weaknesses
9.17 BrainCheck
9.17.1 BrainCheck Details
9.17.2 BrainCheck Major Business
9.17.3 BrainCheck Cognitive Decline Treatment Product and Services
9.17.4 BrainCheck Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.17.5 BrainCheck Recent Developments/Updates
9.17.6 BrainCheck Competitive Strengths & Weaknesses
9.18 Eisai
9.18.1 Eisai Details
9.18.2 Eisai Major Business
9.18.3 Eisai Cognitive Decline Treatment Product and Services
9.18.4 Eisai Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.18.5 Eisai Recent Developments/Updates
9.18.6 Eisai Competitive Strengths & Weaknesses
9.19 Ono Pharmaceutical
9.19.1 Ono Pharmaceutical Details
9.19.2 Ono Pharmaceutical Major Business
9.19.3 Ono Pharmaceutical Cognitive Decline Treatment Product and Services
9.19.4 Ono Pharmaceutical Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.19.5 Ono Pharmaceutical Recent Developments/Updates
9.19.6 Ono Pharmaceutical Competitive Strengths & Weaknesses
9.20 Takeda Pharmaceutical
9.20.1 Takeda Pharmaceutical Details
9.20.2 Takeda Pharmaceutical Major Business
9.20.3 Takeda Pharmaceutical Cognitive Decline Treatment Product and Services
9.20.4 Takeda Pharmaceutical Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.20.5 Takeda Pharmaceutical Recent Developments/Updates
9.20.6 Takeda Pharmaceutical Competitive Strengths & Weaknesses
9.21 SK Biopharmaceuticals
9.21.1 SK Biopharmaceuticals Details
9.21.2 SK Biopharmaceuticals Major Business
9.21.3 SK Biopharmaceuticals Cognitive Decline Treatment Product and Services
9.21.4 SK Biopharmaceuticals Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.21.5 SK Biopharmaceuticals Recent Developments/Updates
9.21.6 SK Biopharmaceuticals Competitive Strengths & Weaknesses
9.22 VUNO
9.22.1 VUNO Details
9.22.2 VUNO Major Business
9.22.3 VUNO Cognitive Decline Treatment Product and Services
9.22.4 VUNO Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.22.5 VUNO Recent Developments/Updates
9.22.6 VUNO Competitive Strengths & Weaknesses
9.23 Ybrain
9.23.1 Ybrain Details
9.23.2 Ybrain Major Business
9.23.3 Ybrain Cognitive Decline Treatment Product and Services
9.23.4 Ybrain Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.23.5 Ybrain Recent Developments/Updates
9.23.6 Ybrain Competitive Strengths & Weaknesses
9.24 Green Valley Pharma
9.24.1 Green Valley Pharma Details
9.24.2 Green Valley Pharma Major Business
9.24.3 Green Valley Pharma Cognitive Decline Treatment Product and Services
9.24.4 Green Valley Pharma Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.24.5 Green Valley Pharma Recent Developments/Updates
9.24.6 Green Valley Pharma Competitive Strengths & Weaknesses
9.25 Neusoft Medical
9.25.1 Neusoft Medical Details
9.25.2 Neusoft Medical Major Business
9.25.3 Neusoft Medical Cognitive Decline Treatment Product and Services
9.25.4 Neusoft Medical Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.25.5 Neusoft Medical Recent Developments/Updates
9.25.6 Neusoft Medical Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Cognitive Decline Treatment Industry Chain
10.2 Cognitive Decline Treatment Upstream Analysis
10.3 Cognitive Decline Treatment Midstream Analysis
10.4 Cognitive Decline Treatment Downstream Analysis
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
LIST OF TABLES
Table 1. World Cognitive Decline Treatment Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Cognitive Decline Treatment Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Cognitive Decline Treatment Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Cognitive Decline Treatment Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Cognitive Decline Treatment Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Cognitive Decline Treatment Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Cognitive Decline Treatment Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Cognitive Decline Treatment Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Cognitive Decline Treatment Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Cognitive Decline Treatment Players in 2025
Table 12. World Cognitive Decline Treatment Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Cognitive Decline Treatment Company Evaluation Quadrant
Table 14. Head Office of Key Cognitive Decline Treatment Players
Table 15. Cognitive Decline Treatment Market: Company Product Type Footprint
Table 16. Cognitive Decline Treatment Market: Company Product Application Footprint
Table 17. Cognitive Decline Treatment Mergers & Acquisitions Activity
Table 18. United States VS China Cognitive Decline Treatment Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Cognitive Decline Treatment Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Cognitive Decline Treatment Companies, Headquarters (States, Country)
Table 21. United States Based Companies Cognitive Decline Treatment Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Cognitive Decline Treatment Revenue Market Share (2021-2026)
Table 23. China Based Cognitive Decline Treatment Companies, Headquarters (Province, Country)
Table 24. China Based Companies Cognitive Decline Treatment Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Cognitive Decline Treatment Revenue Market Share (2021-2026)
Table 26. Rest of World Based Cognitive Decline Treatment Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Cognitive Decline Treatment Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Cognitive Decline Treatment Revenue Market Share (2021-2026)
Table 29. World Cognitive Decline Treatment Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Cognitive Decline Treatment Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Cognitive Decline Treatment Market Size by Type (2027-2032) & (USD Million)
Table 32. World Cognitive Decline Treatment Market Size by Intervention Stages, (USD Million), 2021 & 2025 & 2032
Table 33. World Cognitive Decline Treatment Market Size Value by Intervention Stages (2021-2026) & (USD Million)
Table 34. World Cognitive Decline Treatment Market Size by Intervention Stages (2027-2032) & (USD Million)
Table 35. World Cognitive Decline Treatment Market Size by Technological Pathways, (USD Million), 2021 & 2025 & 2032
Table 36. World Cognitive Decline Treatment Market Size Value by Technological Pathways (2021-2026) & (USD Million)
Table 37. World Cognitive Decline Treatment Market Size by Technological Pathways (2027-2032) & (USD Million)
Table 38. World Cognitive Decline Treatment Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 39. World Cognitive Decline Treatment Market Size by Application (2021-2026) & (USD Million)
Table 40. World Cognitive Decline Treatment Market Size by Application (2027-2032) & (USD Million)
Table 41. Eli Lilly and Company Basic Information, Manufacturing Base and Competitors
Table 42. Eli Lilly and Company Major Business
Table 43. Eli Lilly and Company Cognitive Decline Treatment Product and Services
Table 44. Eli Lilly and Company Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. Eli Lilly and Company Recent Developments/Updates
Table 46. Eli Lilly and Company Competitive Strengths & Weaknesses
Table 47. Eisai Co., Ltd Basic Information, Manufacturing Base and Competitors
Table 48. Eisai Co., Ltd Major Business
Table 49. Eisai Co., Ltd Cognitive Decline Treatment Product and Services
Table 50. Eisai Co., Ltd Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. Eisai Co., Ltd Recent Developments/Updates
Table 52. Eisai Co., Ltd Competitive Strengths & Weaknesses
Table 53. Biogen Inc. Basic Information, Manufacturing Base and Competitors
Table 54. Biogen Inc. Major Business
Table 55. Biogen Inc. Cognitive Decline Treatment Product and Services
Table 56. Biogen Inc. Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. Biogen Inc. Recent Developments/Updates
Table 58. Biogen Inc. Competitive Strengths & Weaknesses
Table 59. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 60. Novartis AG Major Business
Table 61. Novartis AG Cognitive Decline Treatment Product and Services
Table 62. Novartis AG Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. Novartis AG Recent Developments/Updates
Table 64. Novartis AG Competitive Strengths & Weaknesses
Table 65. AbbVie Inc. Basic Information, Manufacturing Base and Competitors
Table 66. AbbVie Inc. Major Business
Table 67. AbbVie Inc. Cognitive Decline Treatment Product and Services
Table 68. AbbVie Inc. Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. AbbVie Inc. Recent Developments/Updates
Table 70. AbbVie Inc. Competitive Strengths & Weaknesses
Table 71. Lundbeck Basic Information, Manufacturing Base and Competitors
Table 72. Lundbeck Major Business
Table 73. Lundbeck Cognitive Decline Treatment Product and Services
Table 74. Lundbeck Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. Lundbeck Recent Developments/Updates
Table 76. Lundbeck Competitive Strengths & Weaknesses
Table 77. Takeda Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 78. Takeda Pharmaceutical Major Business
Table 79. Takeda Pharmaceutical Cognitive Decline Treatment Product and Services
Table 80. Takeda Pharmaceutical Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. Takeda Pharmaceutical Recent Developments/Updates
Table 82. Takeda Pharmaceutical Competitive Strengths & Weaknesses
Table 83. Alzheon Basic Information, Manufacturing Base and Competitors
Table 84. Alzheon Major Business
Table 85. Alzheon Cognitive Decline Treatment Product and Services
Table 86. Alzheon Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. Alzheon Recent Developments/Updates
Table 88. Alzheon Competitive Strengths & Weaknesses
Table 89. TauRx Therapeutics Basic Information, Manufacturing Base and Competitors
Table 90. TauRx Therapeutics Major Business
Table 91. TauRx Therapeutics Cognitive Decline Treatment Product and Services
Table 92. TauRx Therapeutics Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 93. TauRx Therapeutics Recent Developments/Updates
Table 94. TauRx Therapeutics Competitive Strengths & Weaknesses
Table 95. Medtronic Basic Information, Manufacturing Base and Competitors
Table 96. Medtronic Major Business
Table 97. Medtronic Cognitive Decline Treatment Product and Services
Table 98. Medtronic Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 99. Medtronic Recent Developments/Updates
Table 100. Medtronic Competitive Strengths & Weaknesses
Table 101. Abbott Laboratories Basic Information, Manufacturing Base and Competitors
Table 102. Abbott Laboratories Major Business
Table 103. Abbott Laboratories Cognitive Decline Treatment Product and Services
Table 104. Abbott Laboratories Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 105. Abbott Laboratories Recent Developments/Updates
Table 106. Abbott Laboratories Competitive Strengths & Weaknesses
Table 107. Boston Scientific Basic Information, Manufacturing Base and Competitors
Table 108. Boston Scientific Major Business
Table 109. Boston Scientific Cognitive Decline Treatment Product and Services
Table 110. Boston Scientific Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 111. Boston Scientific Recent Developments/Updates
Table 112. Boston Scientific Competitive Strengths & Weaknesses
Table 113. NeuroPace Basic Information, Manufacturing Base and Competitors
Table 114. NeuroPace Major Business
Table 115. NeuroPace Cognitive Decline Treatment Product and Services
Table 116. NeuroPace Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 117. NeuroPace Recent Developments/Updates
Table 118. NeuroPace Competitive Strengths & Weaknesses
Table 119. Posit Science Basic Information, Manufacturing Base and Competitors
Table 120. Posit Science Major Business
Table 121. Posit Science Cognitive Decline Treatment Product and Services
Table 122. Posit Science Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 123. Posit Science Recent Developments/Updates
Table 124. Posit Science Competitive Strengths & Weaknesses
Table 125. CogniFit Basic Information, Manufacturing Base and Competitors
Table 126. CogniFit Major Business
Table 127. CogniFit Cognitive Decline Treatment Product and Services
Table 128. CogniFit Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 129. CogniFit Recent Developments/Updates
Table 130. CogniFit Competitive Strengths & Weaknesses
Table 131. Linus Health Basic Information, Manufacturing Base and Competitors
Table 132. Linus Health Major Business
Table 133. Linus Health Cognitive Decline Treatment Product and Services
Table 134. Linus Health Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 135. Linus Health Recent Developments/Updates
Table 136. Linus Health Competitive Strengths & Weaknesses
Table 137. BrainCheck Basic Information, Manufacturing Base and Competitors
Table 138. BrainCheck Major Business
Table 139. BrainCheck Cognitive Decline Treatment Product and Services
Table 140. BrainCheck Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 141. BrainCheck Recent Developments/Updates
Table 142. BrainCheck Competitive Strengths & Weaknesses
Table 143. Eisai Basic Information, Manufacturing Base and Competitors
Table 144. Eisai Major Business
Table 145. Eisai Cognitive Decline Treatment Product and Services
Table 146. Eisai Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 147. Eisai Recent Developments/Updates
Table 148. Eisai Competitive Strengths & Weaknesses
Table 149. Ono Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 150. Ono Pharmaceutical Major Business
Table 151. Ono Pharmaceutical Cognitive Decline Treatment Product and Services
Table 152. Ono Pharmaceutical Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 153. Ono Pharmaceutical Recent Developments/Updates
Table 154. Ono Pharmaceutical Competitive Strengths & Weaknesses
Table 155. Takeda Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 156. Takeda Pharmaceutical Major Business
Table 157. Takeda Pharmaceutical Cognitive Decline Treatment Product and Services
Table 158. Takeda Pharmaceutical Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 159. Takeda Pharmaceutical Recent Developments/Updates
Table 160. Takeda Pharmaceutical Competitive Strengths & Weaknesses
Table 161. SK Biopharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 162. SK Biopharmaceuticals Major Business
Table 163. SK Biopharmaceuticals Cognitive Decline Treatment Product and Services
Table 164. SK Biopharmaceuticals Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 165. SK Biopharmaceuticals Recent Developments/Updates
Table 166. SK Biopharmaceuticals Competitive Strengths & Weaknesses
Table 167. VUNO Basic Information, Manufacturing Base and Competitors
Table 168. VUNO Major Business
Table 169. VUNO Cognitive Decline Treatment Product and Services
Table 170. VUNO Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 171. VUNO Recent Developments/Updates
Table 172. VUNO Competitive Strengths & Weaknesses
Table 173. Ybrain Basic Information, Manufacturing Base and Competitors
Table 174. Ybrain Major Business
Table 175. Ybrain Cognitive Decline Treatment Product and Services
Table 176. Ybrain Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 177. Ybrain Recent Developments/Updates
Table 178. Ybrain Competitive Strengths & Weaknesses
Table 179. Green Valley Pharma Basic Information, Manufacturing Base and Competitors
Table 180. Green Valley Pharma Major Business
Table 181. Green Valley Pharma Cognitive Decline Treatment Product and Services
Table 182. Green Valley Pharma Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 183. Green Valley Pharma Recent Developments/Updates
Table 184. Green Valley Pharma Competitive Strengths & Weaknesses
Table 185. Neusoft Medical Basic Information, Manufacturing Base and Competitors
Table 186. Neusoft Medical Major Business
Table 187. Neusoft Medical Cognitive Decline Treatment Product and Services
Table 188. Neusoft Medical Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 189. Neusoft Medical Recent Developments/Updates
Table 190. Neusoft Medical Competitive Strengths & Weaknesses
Table 191. Global Key Players of Cognitive Decline Treatment Upstream (Raw Materials)
Table 192. Global Cognitive Decline Treatment Typical Customers
Table 1. World Cognitive Decline Treatment Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Cognitive Decline Treatment Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Cognitive Decline Treatment Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Cognitive Decline Treatment Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Cognitive Decline Treatment Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Cognitive Decline Treatment Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Cognitive Decline Treatment Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Cognitive Decline Treatment Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Cognitive Decline Treatment Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Cognitive Decline Treatment Players in 2025
Table 12. World Cognitive Decline Treatment Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Cognitive Decline Treatment Company Evaluation Quadrant
Table 14. Head Office of Key Cognitive Decline Treatment Players
Table 15. Cognitive Decline Treatment Market: Company Product Type Footprint
Table 16. Cognitive Decline Treatment Market: Company Product Application Footprint
Table 17. Cognitive Decline Treatment Mergers & Acquisitions Activity
Table 18. United States VS China Cognitive Decline Treatment Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Cognitive Decline Treatment Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Cognitive Decline Treatment Companies, Headquarters (States, Country)
Table 21. United States Based Companies Cognitive Decline Treatment Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Cognitive Decline Treatment Revenue Market Share (2021-2026)
Table 23. China Based Cognitive Decline Treatment Companies, Headquarters (Province, Country)
Table 24. China Based Companies Cognitive Decline Treatment Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Cognitive Decline Treatment Revenue Market Share (2021-2026)
Table 26. Rest of World Based Cognitive Decline Treatment Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Cognitive Decline Treatment Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Cognitive Decline Treatment Revenue Market Share (2021-2026)
Table 29. World Cognitive Decline Treatment Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Cognitive Decline Treatment Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Cognitive Decline Treatment Market Size by Type (2027-2032) & (USD Million)
Table 32. World Cognitive Decline Treatment Market Size by Intervention Stages, (USD Million), 2021 & 2025 & 2032
Table 33. World Cognitive Decline Treatment Market Size Value by Intervention Stages (2021-2026) & (USD Million)
Table 34. World Cognitive Decline Treatment Market Size by Intervention Stages (2027-2032) & (USD Million)
Table 35. World Cognitive Decline Treatment Market Size by Technological Pathways, (USD Million), 2021 & 2025 & 2032
Table 36. World Cognitive Decline Treatment Market Size Value by Technological Pathways (2021-2026) & (USD Million)
Table 37. World Cognitive Decline Treatment Market Size by Technological Pathways (2027-2032) & (USD Million)
Table 38. World Cognitive Decline Treatment Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 39. World Cognitive Decline Treatment Market Size by Application (2021-2026) & (USD Million)
Table 40. World Cognitive Decline Treatment Market Size by Application (2027-2032) & (USD Million)
Table 41. Eli Lilly and Company Basic Information, Manufacturing Base and Competitors
Table 42. Eli Lilly and Company Major Business
Table 43. Eli Lilly and Company Cognitive Decline Treatment Product and Services
Table 44. Eli Lilly and Company Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. Eli Lilly and Company Recent Developments/Updates
Table 46. Eli Lilly and Company Competitive Strengths & Weaknesses
Table 47. Eisai Co., Ltd Basic Information, Manufacturing Base and Competitors
Table 48. Eisai Co., Ltd Major Business
Table 49. Eisai Co., Ltd Cognitive Decline Treatment Product and Services
Table 50. Eisai Co., Ltd Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. Eisai Co., Ltd Recent Developments/Updates
Table 52. Eisai Co., Ltd Competitive Strengths & Weaknesses
Table 53. Biogen Inc. Basic Information, Manufacturing Base and Competitors
Table 54. Biogen Inc. Major Business
Table 55. Biogen Inc. Cognitive Decline Treatment Product and Services
Table 56. Biogen Inc. Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. Biogen Inc. Recent Developments/Updates
Table 58. Biogen Inc. Competitive Strengths & Weaknesses
Table 59. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 60. Novartis AG Major Business
Table 61. Novartis AG Cognitive Decline Treatment Product and Services
Table 62. Novartis AG Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. Novartis AG Recent Developments/Updates
Table 64. Novartis AG Competitive Strengths & Weaknesses
Table 65. AbbVie Inc. Basic Information, Manufacturing Base and Competitors
Table 66. AbbVie Inc. Major Business
Table 67. AbbVie Inc. Cognitive Decline Treatment Product and Services
Table 68. AbbVie Inc. Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. AbbVie Inc. Recent Developments/Updates
Table 70. AbbVie Inc. Competitive Strengths & Weaknesses
Table 71. Lundbeck Basic Information, Manufacturing Base and Competitors
Table 72. Lundbeck Major Business
Table 73. Lundbeck Cognitive Decline Treatment Product and Services
Table 74. Lundbeck Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. Lundbeck Recent Developments/Updates
Table 76. Lundbeck Competitive Strengths & Weaknesses
Table 77. Takeda Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 78. Takeda Pharmaceutical Major Business
Table 79. Takeda Pharmaceutical Cognitive Decline Treatment Product and Services
Table 80. Takeda Pharmaceutical Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. Takeda Pharmaceutical Recent Developments/Updates
Table 82. Takeda Pharmaceutical Competitive Strengths & Weaknesses
Table 83. Alzheon Basic Information, Manufacturing Base and Competitors
Table 84. Alzheon Major Business
Table 85. Alzheon Cognitive Decline Treatment Product and Services
Table 86. Alzheon Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. Alzheon Recent Developments/Updates
Table 88. Alzheon Competitive Strengths & Weaknesses
Table 89. TauRx Therapeutics Basic Information, Manufacturing Base and Competitors
Table 90. TauRx Therapeutics Major Business
Table 91. TauRx Therapeutics Cognitive Decline Treatment Product and Services
Table 92. TauRx Therapeutics Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 93. TauRx Therapeutics Recent Developments/Updates
Table 94. TauRx Therapeutics Competitive Strengths & Weaknesses
Table 95. Medtronic Basic Information, Manufacturing Base and Competitors
Table 96. Medtronic Major Business
Table 97. Medtronic Cognitive Decline Treatment Product and Services
Table 98. Medtronic Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 99. Medtronic Recent Developments/Updates
Table 100. Medtronic Competitive Strengths & Weaknesses
Table 101. Abbott Laboratories Basic Information, Manufacturing Base and Competitors
Table 102. Abbott Laboratories Major Business
Table 103. Abbott Laboratories Cognitive Decline Treatment Product and Services
Table 104. Abbott Laboratories Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 105. Abbott Laboratories Recent Developments/Updates
Table 106. Abbott Laboratories Competitive Strengths & Weaknesses
Table 107. Boston Scientific Basic Information, Manufacturing Base and Competitors
Table 108. Boston Scientific Major Business
Table 109. Boston Scientific Cognitive Decline Treatment Product and Services
Table 110. Boston Scientific Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 111. Boston Scientific Recent Developments/Updates
Table 112. Boston Scientific Competitive Strengths & Weaknesses
Table 113. NeuroPace Basic Information, Manufacturing Base and Competitors
Table 114. NeuroPace Major Business
Table 115. NeuroPace Cognitive Decline Treatment Product and Services
Table 116. NeuroPace Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 117. NeuroPace Recent Developments/Updates
Table 118. NeuroPace Competitive Strengths & Weaknesses
Table 119. Posit Science Basic Information, Manufacturing Base and Competitors
Table 120. Posit Science Major Business
Table 121. Posit Science Cognitive Decline Treatment Product and Services
Table 122. Posit Science Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 123. Posit Science Recent Developments/Updates
Table 124. Posit Science Competitive Strengths & Weaknesses
Table 125. CogniFit Basic Information, Manufacturing Base and Competitors
Table 126. CogniFit Major Business
Table 127. CogniFit Cognitive Decline Treatment Product and Services
Table 128. CogniFit Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 129. CogniFit Recent Developments/Updates
Table 130. CogniFit Competitive Strengths & Weaknesses
Table 131. Linus Health Basic Information, Manufacturing Base and Competitors
Table 132. Linus Health Major Business
Table 133. Linus Health Cognitive Decline Treatment Product and Services
Table 134. Linus Health Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 135. Linus Health Recent Developments/Updates
Table 136. Linus Health Competitive Strengths & Weaknesses
Table 137. BrainCheck Basic Information, Manufacturing Base and Competitors
Table 138. BrainCheck Major Business
Table 139. BrainCheck Cognitive Decline Treatment Product and Services
Table 140. BrainCheck Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 141. BrainCheck Recent Developments/Updates
Table 142. BrainCheck Competitive Strengths & Weaknesses
Table 143. Eisai Basic Information, Manufacturing Base and Competitors
Table 144. Eisai Major Business
Table 145. Eisai Cognitive Decline Treatment Product and Services
Table 146. Eisai Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 147. Eisai Recent Developments/Updates
Table 148. Eisai Competitive Strengths & Weaknesses
Table 149. Ono Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 150. Ono Pharmaceutical Major Business
Table 151. Ono Pharmaceutical Cognitive Decline Treatment Product and Services
Table 152. Ono Pharmaceutical Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 153. Ono Pharmaceutical Recent Developments/Updates
Table 154. Ono Pharmaceutical Competitive Strengths & Weaknesses
Table 155. Takeda Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 156. Takeda Pharmaceutical Major Business
Table 157. Takeda Pharmaceutical Cognitive Decline Treatment Product and Services
Table 158. Takeda Pharmaceutical Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 159. Takeda Pharmaceutical Recent Developments/Updates
Table 160. Takeda Pharmaceutical Competitive Strengths & Weaknesses
Table 161. SK Biopharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 162. SK Biopharmaceuticals Major Business
Table 163. SK Biopharmaceuticals Cognitive Decline Treatment Product and Services
Table 164. SK Biopharmaceuticals Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 165. SK Biopharmaceuticals Recent Developments/Updates
Table 166. SK Biopharmaceuticals Competitive Strengths & Weaknesses
Table 167. VUNO Basic Information, Manufacturing Base and Competitors
Table 168. VUNO Major Business
Table 169. VUNO Cognitive Decline Treatment Product and Services
Table 170. VUNO Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 171. VUNO Recent Developments/Updates
Table 172. VUNO Competitive Strengths & Weaknesses
Table 173. Ybrain Basic Information, Manufacturing Base and Competitors
Table 174. Ybrain Major Business
Table 175. Ybrain Cognitive Decline Treatment Product and Services
Table 176. Ybrain Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 177. Ybrain Recent Developments/Updates
Table 178. Ybrain Competitive Strengths & Weaknesses
Table 179. Green Valley Pharma Basic Information, Manufacturing Base and Competitors
Table 180. Green Valley Pharma Major Business
Table 181. Green Valley Pharma Cognitive Decline Treatment Product and Services
Table 182. Green Valley Pharma Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 183. Green Valley Pharma Recent Developments/Updates
Table 184. Green Valley Pharma Competitive Strengths & Weaknesses
Table 185. Neusoft Medical Basic Information, Manufacturing Base and Competitors
Table 186. Neusoft Medical Major Business
Table 187. Neusoft Medical Cognitive Decline Treatment Product and Services
Table 188. Neusoft Medical Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 189. Neusoft Medical Recent Developments/Updates
Table 190. Neusoft Medical Competitive Strengths & Weaknesses
Table 191. Global Key Players of Cognitive Decline Treatment Upstream (Raw Materials)
Table 192. Global Cognitive Decline Treatment Typical Customers
LIST OF FIGURES
Figure 1. Cognitive Decline Treatment Picture
Figure 2. World Cognitive Decline Treatment Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Cognitive Decline Treatment Total Revenue (2021-2032) & (USD Million)
Figure 4. World Cognitive Decline Treatment Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Cognitive Decline Treatment Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Cognitive Decline Treatment Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Cognitive Decline Treatment Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Cognitive Decline Treatment Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Cognitive Decline Treatment Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Cognitive Decline Treatment Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Cognitive Decline Treatment Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Cognitive Decline Treatment Revenue (2021-2032) & (USD Million)
Figure 13. Cognitive Decline Treatment Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Cognitive Decline Treatment Consumption Value (2021-2032) & (USD Million)
Figure 16. World Cognitive Decline Treatment Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Cognitive Decline Treatment Consumption Value (2021-2032) & (USD Million)
Figure 18. China Cognitive Decline Treatment Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Cognitive Decline Treatment Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Cognitive Decline Treatment Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Cognitive Decline Treatment Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Cognitive Decline Treatment Consumption Value (2021-2032) & (USD Million)
Figure 23. India Cognitive Decline Treatment Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Cognitive Decline Treatment by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Cognitive Decline Treatment Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Cognitive Decline Treatment Markets in 2025
Figure 27. United States VS China: Cognitive Decline Treatment Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Cognitive Decline Treatment Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Cognitive Decline Treatment Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Cognitive Decline Treatment Market Size Market Share by Type in 2025
Figure 31. Prescription Drugs
Figure 32. Medical Devices
Figure 33. Digital Therapy Software
Figure 34. Rehabilitation Training Services
Figure 35. Others
Figure 36. World Cognitive Decline Treatment Market Size Market Share by Type (2021-2032)
Figure 37. World Cognitive Decline Treatment Market Size by Intervention Stages, (USD Million), 2021 & 2025 & 2032
Figure 38. World Cognitive Decline Treatment Market Size Market Share by Intervention Stages in 2025
Figure 39. Prevention Stage
Figure 40. Early Intervention
Figure 41. Intermediate Treatment
Figure 42. Late-Stage Supportive Treatment
Figure 43. World Cognitive Decline Treatment Market Size Market Share by Intervention Stages (2021-2032)
Figure 44. World Cognitive Decline Treatment Market Size by Technological Pathways, (USD Million), 2021 & 2025 & 2032
Figure 45. World Cognitive Decline Treatment Market Size Market Share by Technological Pathways in 2025
Figure 46. Neurotransmitter Regulation Pathway
Figure 47. Amyloid (A?) Clearance Pathway
Figure 48. Tau Protein Targeting Pathway
Figure 49. Neuroinflammatory Regulation Pathway
Figure 50. Neuroplasticity Enhancement Pathway
Figure 51. World Cognitive Decline Treatment Market Size Market Share by Technological Pathways (2021-2032)
Figure 52. World Cognitive Decline Treatment Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 53. World Cognitive Decline Treatment Market Size Market Share by Application in 2025
Figure 54. Alzheimer's Disease (AD)
Figure 55. Vascular Cognitive Impairment (VCI)
Figure 56. Parkinson's-Related Cognitive Decline
Figure 57. Post-Traumatic Brain Injury Cognitive Impairment
Figure 58. Mild Cognitive Impairment (MCI)
Figure 59. World Cognitive Decline Treatment Market Size Market Share by Application (2021-2032)
Figure 60. Cognitive Decline Treatment Industrial Chain
Figure 61. Methodology
Figure 62. Research Process and Data Source
Figure 1. Cognitive Decline Treatment Picture
Figure 2. World Cognitive Decline Treatment Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Cognitive Decline Treatment Total Revenue (2021-2032) & (USD Million)
Figure 4. World Cognitive Decline Treatment Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Cognitive Decline Treatment Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Cognitive Decline Treatment Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Cognitive Decline Treatment Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Cognitive Decline Treatment Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Cognitive Decline Treatment Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Cognitive Decline Treatment Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Cognitive Decline Treatment Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Cognitive Decline Treatment Revenue (2021-2032) & (USD Million)
Figure 13. Cognitive Decline Treatment Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Cognitive Decline Treatment Consumption Value (2021-2032) & (USD Million)
Figure 16. World Cognitive Decline Treatment Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Cognitive Decline Treatment Consumption Value (2021-2032) & (USD Million)
Figure 18. China Cognitive Decline Treatment Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Cognitive Decline Treatment Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Cognitive Decline Treatment Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Cognitive Decline Treatment Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Cognitive Decline Treatment Consumption Value (2021-2032) & (USD Million)
Figure 23. India Cognitive Decline Treatment Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Cognitive Decline Treatment by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Cognitive Decline Treatment Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Cognitive Decline Treatment Markets in 2025
Figure 27. United States VS China: Cognitive Decline Treatment Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Cognitive Decline Treatment Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Cognitive Decline Treatment Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Cognitive Decline Treatment Market Size Market Share by Type in 2025
Figure 31. Prescription Drugs
Figure 32. Medical Devices
Figure 33. Digital Therapy Software
Figure 34. Rehabilitation Training Services
Figure 35. Others
Figure 36. World Cognitive Decline Treatment Market Size Market Share by Type (2021-2032)
Figure 37. World Cognitive Decline Treatment Market Size by Intervention Stages, (USD Million), 2021 & 2025 & 2032
Figure 38. World Cognitive Decline Treatment Market Size Market Share by Intervention Stages in 2025
Figure 39. Prevention Stage
Figure 40. Early Intervention
Figure 41. Intermediate Treatment
Figure 42. Late-Stage Supportive Treatment
Figure 43. World Cognitive Decline Treatment Market Size Market Share by Intervention Stages (2021-2032)
Figure 44. World Cognitive Decline Treatment Market Size by Technological Pathways, (USD Million), 2021 & 2025 & 2032
Figure 45. World Cognitive Decline Treatment Market Size Market Share by Technological Pathways in 2025
Figure 46. Neurotransmitter Regulation Pathway
Figure 47. Amyloid (A?) Clearance Pathway
Figure 48. Tau Protein Targeting Pathway
Figure 49. Neuroinflammatory Regulation Pathway
Figure 50. Neuroplasticity Enhancement Pathway
Figure 51. World Cognitive Decline Treatment Market Size Market Share by Technological Pathways (2021-2032)
Figure 52. World Cognitive Decline Treatment Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 53. World Cognitive Decline Treatment Market Size Market Share by Application in 2025
Figure 54. Alzheimer's Disease (AD)
Figure 55. Vascular Cognitive Impairment (VCI)
Figure 56. Parkinson's-Related Cognitive Decline
Figure 57. Post-Traumatic Brain Injury Cognitive Impairment
Figure 58. Mild Cognitive Impairment (MCI)
Figure 59. World Cognitive Decline Treatment Market Size Market Share by Application (2021-2032)
Figure 60. Cognitive Decline Treatment Industrial Chain
Figure 61. Methodology
Figure 62. Research Process and Data Source
